Navigation Links
Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
Date:1/5/2011

PITTSBURGH, Jan. 5, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has notified The Nasdaq Stock Market, an exchange of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ), that it intends to voluntarily de-list its 1.25% Senior Convertible Notes due 2012 from the Nasdaq Capital Market, on which the notes trade under the ticker symbol "MYLNG," effective as of the open of trading on January 28, 2011. The notes will continue to trade over-the-counter (OTC) with trade data available through the Financial Industry Regulatory Authority's Trade Reporting and Compliance Engine ("TRACE"). Moving the trading of the notes from Nasdaq to the OTC market will bring the company in line with standard capital markets practice and reduce the company's regulatory burden.  

On January 5, 2011, Nasdaq notified the company that the notes did not have the number of market makers required by Nasdaq's continued listing standards. While there are multiple securities firms that regularly trade the notes, these firms do not meet the strict criteria required of a market maker under Nasdaq's listing standards. The de-listing of the notes from Nasdaq does not affect the listing or trading of the company's common stock, ticker symbol "MYL," which will continue uninterrupted on Nasdaq.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
2. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
3. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
4. Mylan Announces the Conversion of its Preferred Stock into Common Stock
5. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
6. Third Circuit Denies Mylan Motion for Interim Injunction
7. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
10. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
11. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 Now ... the pharmaceutical companies that are most successful at developing and ... ... you gave the same molecule to two different companies in ... Based on systematic, objective analysis of each company,s performance ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Ind. , Feb. 24, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the Cowen ... at the Boston Marriott Copley Place on Tuesday, March ... A live webcast of the presentation can be ... archived for replay following the conference via Zimmer Biomet,s ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... hair transplantation therapy, is proud to announce a new informational post on robotic ... procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can ...
(Date:2/27/2017)... ... 27, 2017 , ... New Jersey ranks among the top five states in ... the need for advanced services is growing. , Project WE vs C is ... collaboration with their non-profit partners in their fight against cancer and in support of ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design ... Edition of International Social Design Awards. , The 7th A' Social Design ... Governments and Institutions worldwide with realized projects and conceptual works. , The first ...
Breaking Medicine News(10 mins):